Press Release

NEW YORK and LONDON, July 13, 2015 Celsus Therapeutics (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a …

[Read more...] about Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Agreement to Create Orphan Disease Company Focused on Complement C5 Inhibition

MRX-6 Cream Did Not Demonstrate Separation from Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment NEW YORK and …

[Read more...] about Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint

NEW YORK and LONDON, January 13, 2015 Topline data from double-blind portion of trial expected by end of February, 2015 Celsus Therapeutics (NASDAQ: …

[Read more...] about Celsus Therapeutics Completes Enrollment of Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis

NEW YORK and LONDON, January 12, 2015 Phase II dose ranging clinical trial in atopic dermatitis expected to begin in first quarter of 2015 Celsus …

[Read more...] about Celsus Therapeutics Announces FDA Allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis

NEW YORK and LONDON, December 2, 2014 Celsus Therapeutics (NASDAQ: CLTX), an emerging growth, development-stage biopharmaceutical company, announces that Gur …

[Read more...] about Celsus Therapeutics Announces Upcoming Presentation at Oppenheimer 25th Annual Healthcare Conference